How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-fenofibrate-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Comparator: fenofibrate monotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparator: fenofibrate monotherapy (Comparator: fenofibrate monotherapy) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fibrate (PPARα agonist). Area: Cardiovascular.

phase 3 Fibrate (PPARα agonist) PPARα (Peroxisome proliferator-activated receptor alpha) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: fenofibrate monotherapy (Comparator: fenofibrate monotherapy) — Organon and Co. Fenofibrate is a fibric acid derivative that activates peroxisome proliferator-activated receptor alpha (PPARα) to reduce triglycerides and increase HDL cholesterol.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: fenofibrate monotherapy TARGET	Comparator: fenofibrate monotherapy	Organon and Co	phase 3	Fibrate (PPARα agonist)	PPARα (Peroxisome proliferator-activated receptor alpha)
ANTARA® (fenofibrate)	ANTARA® (fenofibrate)	Ranbaxy Laboratories Limited	marketed	Fibrate (PPARα agonist)	PPARα (Peroxisome proliferator-activated receptor alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fibrate (PPARα agonist) class)

Organon and Co · 1 drug in this class
Ranbaxy Laboratories Limited · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: fenofibrate monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-fenofibrate-monotherapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing